IDEAYA Biosciences, Inc.
IDYAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeIDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. With a market capitalization of $2.54B, it sits in mid-cap territory. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Market Cap
$2.54B
Beta
-0.04
P/E (TTM)
—
P/E (Fwd)
-7.75
EPS (TTM)
$-1.57
EPS (Fwd)
$-3.73
ROE
-14.3%
ROA
-10.8%
Cash
$671.2M
Total Debt
$28.6M
Free CF
-$57.3M
52W Change
33.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $671.2M in cash comfortably exceeding the $28.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$57.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -14.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $50.9M to $218.7M.
With a beta below 0.7, IDEAYA Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, IDYA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing IDYA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.